Jihua Chen (Regeneron, NY, USA) author of ‘Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH’ published in Bioanalysis gives us an insight into his research and some of the major challenges in the field.
Author Montserrat Carrasco-Triguero (Genentech, CA, USA) gives us an insight into her research career and her paper published in Bioanalysis: Immunogenicity of antibody–drug conjugates: observations across 8 molecules in 11 clinical trials, in this author’s perspective feature.
This infographic highlights the key qualities to look for in a CRO to ensure the best results when outsourcing immunogenicity assay development and testing.
In this podcast, Steven Kleiboeker (Vice-President of Research and Development at Viracor Eurofins BioPharma Services,…
In this article from Bioanalysis, the authors give their perspectives and findings in exploring a hybrid LBA/LC–MS as an orthogonal bioanalytical tool for clinical immunogenicity assessments.
In this interview, Jon Haulenbeek (Bristol-Myers Squibb; NJ, USA) discusses his role as a Group Leader running the Reagent Center of Excellence in the Translational Medicine Division.
In this editorial Sally Fischer (Genentech; CA, USA) explores ligand binding assay technologies: how to match the right tool to the bioanalytical challenge.
2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity)
This part of the 2018 White Paper published in Bioanalysis focuses on the recommendations for PK, PD and ADA assays by hybrid LBA/LCMS and regulatory agencies’ input.
The speakers from our January panel discussion on immunogenicity answer further questions from the live event
Thermo Fisher Scientific (MA, USA) have announced the launch of a new complementary diagnostic immunoassay, the Thermo Scientific QMS Plazomicin Immunoassay, for measuring the concentration of a novel therapeutic antibiotic, plazomicin, used to treat complicated urinary tract infections.